ArticleJournal of neuro-oncology2010
Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
Article in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Immunohistochemical Staining Properties of Osteopontin and Ki-67 in Feline Meningiomas.Animals : an open access journal from MDPI · 2024Article
- Meningioma-Brain Crosstalk: A Scoping Review.Cancers · 2021Article
- CD44 Expression in Meningioma and its Correlation with Proliferation Indices.Journal of clinical and diagnostic research : JCDR · 2017Article
- Pathology and molecular genetics of meningioma: recent advances.Neurologia medico-chirurgica · 2015Review
- Are Osteopontin and Ki67 Expressions Different in Various Histologic Grades of Meningioma? An Iranian Experience.Iranian journal of pathology · 2015Article
- EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas.Journal of neuro-oncology · 2013Article
- Gene expression analysis of aberrant signaling pathways in meningiomas.Oncology letters · 2013Article
- Meningioma.Current neurology and neuroscience reports · 2013Review
- Proteins involved in regulating bone invasion in skull base meningiomas.Acta neurochirurgica · 2013Article
- Osteoblastic meningiomas: clinico-pathological and immunohistochemical features of an uncommon variant.Journal of neuro-oncology · 2011Article
- Isolation and characterization of tumor stem-like cells from human meningiomas.Journal of neuro-oncology · 2011Article
- Inhibition of Nodal suppresses angiogenesis and growth of human gliomas.Journal of neuro-oncology · 2011Article
- DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.The oncologist · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prediction of recurrence remains a challenge in histopathological benign/grade I tumors. Osteopontin (OPN) plays important roles in tumorigenesis, invasion, and metastasis of several human cancers. In this study, we investigated OPN protein expression by evaluating the differences between recurrent and non-recurrent histologically benign meningiomas. Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II). Cytoplasmic OPN staining was evaluated by means of immunohistochemistry (IHC) score and by use of the Allred-8-unit system. We examined clinical biological data, their relationship with tumor recurrence, and the expression of OPN. Our results showed that meningioma recurrence correlated significantly with OPN IHC score (P = 0.001). An OPN Allred score between 0 and 3 was associated with a recurrence-free time of more than 25 months. In comparison, an OPN Allred score from 4 to 8 was indicative of a shorter average recurrence-free time. We concluded that OPN IHC score may play a role in prediction of the recurrence of the grade I meningiomas. Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.